Wacker doubles production area at biologics plant
Wacker Chemie officially opens its new biologics plant in Jena, Germany.
The firm says the expansion will enable it to meet growing demand for biologically manufactured pharmaceuticals used to treat cancer, multiple sclerosis and hepatitis, among other indications.
The expansion, together with a building for process development and quality control completed last year, brings the total investment at the plant to Euro 18m.
Wacker has almost doubled the production area at the GMP-certified site. A new facility for product purification also allows up to three times higher product yields per batch.
"Demand for advanced biotech products is growing worldwide. Innovative, biotechnological processes such as Wacker's ESETEC secretion system allow us to meet demand and continue to shape the developments in biotechnology here in Germany," said Auguste Williams, a member of Wacker's Executive Board.
"We now have an ideal system for developing the sophisticated processes and analytical techniques of modern, microbe-based biologics," added Thomas Maier, managing director of Wacker Biotech.
"This allows Wacker to optimise the entire process chain, from lab operations to industrial GMP production. Customers thus benefit from a full process and analysis package provided from a single source. And with the expansion of our production capacities, we can now make our innovative ESETEC secretion technology available to more customers."
Traditional production methods aside, the focus of the new unit is on Wacker's ESETEC and DENSETEC proprietary technologies, which enable simpler, more cost-efficient and high-yield production of biologics for the pharmaceuticals industry.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing
Piramal Pharma Solutions announces partnership with Botanix to support drug substance development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Manufacturing
ProtaGene and Merck partner to deliver end-to-end biologics testing
The duo will combine ProtaGene's early-stage biologics expertise with Merck's BioReliance GMP testing infrastructure, offering biopharmaceutical customers an integrated testing solution across the full drug development lifecycle